Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity
Acute peripheral neuropathy often does not resolve between cycles of treatment and severity often increases between cycles.
A prescription drug's label AE section is almost entirely based on clinicians' impression of patients' symptoms, not the patients' own reports.
Gastrointestinal Cancers News
[Gastrointestinal Cancer: Targets and Therapy] Obesity is now recognized as one of the foremost modifiable cancer risk factors.
More Gastrointestinal Cancers Information
A fact sheet to review the different types of test used to detect colon cancer and polyps.
This fact sheet helps patients with metastatic colorectal cancer to learn more about personalized medicine and KRAS gene testing.
This fact sheet explains the importance of screening for colorectal/rectal/bowel cancer causes, symptoms, and risk factors.
This fact sheet offers tips for coping with colorectal cancer, diagnosis, treatment, and symptoms.
This patient information fact sheet provides information on stomach cancer, causes, diagnosis, ulcers, symptoms, and treatment.
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- FDA Grants Breakthrough Therapy Designation to Cabozantinib for Renal Cell Carcinoma
- In Fit Patients With NSCLC, Erlotinib Not Recommended
- Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity
- New Hormonal Agents for Prostate Cancer May Increase Risk of Cardiotoxicity
- Dasatinib-induced Pulmonary Hypertension in Patients With Leukemia
- Molecular Profiles Can be Used for Early Detection for Aggressive Prostate Cancer
- Thyroid Carcinoma Treatment Regimens
- Combining Aromatase Inhibitors, Bisphosphonates May Benefit Women With Breast Cancer
- Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology
- A Decade of Dramatic Change in the Treatment of Prostate Cancer
- Immunotherapy Combinations for Renal Cell Carcinoma Offer Promise, Challenges
- Association of 21-Gene Recurrence Score Assay, Chemo in Early-stage Breast Cancer
- In Heavily Pretreated Refractory Myeloma, Daratumumab May Be Safe, Effective
- In Locoregionally Advanced Oral Cavity Cancer, Preop Induction Chemo May Not Improve Outcomes
- Patients With Solid Tumors Face Risk for Critical Illness
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|